# A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)

> **NCT04476017** · PHASE2 · COMPLETED · sponsor: **Supernus Pharmaceuticals, Inc.** · enrollment: 18 (actual)

## Conditions studied

- Parkinson Disease
- Cognitive Dysfunction

## Interventions

- **DRUG:** SAGE-718

## Key facts

- **NCT ID:** NCT04476017
- **Lead sponsor:** Supernus Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-31
- **Primary completion:** 2022-03-25
- **Final completion:** 2022-03-25
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2025-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04476017

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04476017, "A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment (PD-MCI)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04476017. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*